Delta4 | AI Drug Discovery & Indication Expansion
Leveraging AI to discover new indications for drugs with known safety profiles.
Iguratimod Case Study:
Identifying The Treatments of Tomorrow, Today!
Delta4, a frontrunner in the TechBio realm, unveiled potential new indications for the drug Iguratimod using its AI-powered in-silico platform, Hyper-C. Tapping into sophisticated algorithms, Hyper-C meticulously analyzed the Iguratimod drug model against an extensive catalog of disease profiles, pinpointing potential avenues for indication expansion. This data potentially revolutionizes how we perceive and utilize Iguratimod in the medical field.
Dive into our video presentation to uncover the intricate processes by which Hyper-C made these revelations and explore the promising new indications. Don’t miss out on this exciting journey into the future of drug indication expansion!
Download Our Report
What We Do
Delta4 is an AI drug discovery TechBio company.
We focus on discovering undetected relationships between drugs with a known safety profile and diseases to identify new indications. We do this by utilizing Hyper-C, our artificial intelligence powered platform that allows us to detect these relationships with unprecedented speed.
Hyper-C is operated by our team of highly skilled computational biologists who carefully analyze the data to produce unique insights and detect drug indication expansion opportunities.
The results are new therapy options that find their way to patients faster, more cost-effectively, and more efficiently than ever before.
Hyper-C | Our Platform
Intelligent systems for unparalleled results.
Hyper-C stands for Hyper Connectivity. It’s our proprietary AI platform housing an enormous collection of algorithmic intelligence.
The platform feeds on big data and uses its algorithms and data integration to build molecular models which go through an iterative refinement process matching them to diseases. This sophisticated process utilizing thousands of pre-computed models effectively matches compounds to diseases for more efficient biological testing and clinical trials.
Hyper-C is unique in that unlike other AI platforms, it eliminates the black box problem. Its results provide a clear mechanism of action hypothesis that aids in regulatory requirements.
In-silico AI platform
De-risking with existing safety profiles
70 man-years of development
In-silico AI platform
De-risking with existing safety profiles
70 man-years of development
Learn more about our platform, the exceptional team that operates it, and how it can help you identify new indications for compounds with a higher probability of success in the biological testing and clinical phases.
Our Process
An efficient and cost-effective methodology streamlined for success
Previous slide
Next slide
Learn more about our process and our pipeline of assets to see what we’re working on.
Who We Are
Crafting the treatments of the future.
Delta4 is a TechBio company focused on expanding indications for existing drugs with known safety profiles.
We accelerate new treatment options to improve the health of patients and get them into their hands faster, more safely, and more efficiently than the traditional approach.
Our Partners & Clients
It’s an honor and a privilege to be working with the best of the best!
Proud Member of Scientist.com
Streamlining Transparency and Cooperation
Scientist.com provides a unique platform where researchers and suppliers can both find each other and work together more easily. They provide a collaboration framework to streamline the typically long and tedious process of defining the terms and conditions of an agreement.
Members can work together smoothly and effortlessly by agreeing to the rules of the platform. The result is that together we can achieve the results we need faster.
Latest News & Events
Stay up to date with all our activities
From the latest news and press releases to blog posts and important industry events, check here to stay current with what we’re up to and what we’re watching.
Digital Health Envision Summit
We are delighted to announce that Kurt Herpel, CEO, and Dr. Paul Perco, Computational Biology Lead of Delta4, are looking ...
Read More
Case Study: Unravelling the Multifaceted Potential of Iguratimod with Delta4’s Hyper-C Platform
Diving deep into the realms of computational drug repurposing, Delta4 leveraged its state-of-the-art Hyper-C platform with an ambitious objective: to ...
Read More
Delta4 At BIO-Europe
Delta4 Will Attend BIO-Europe 2023 Delta4 is thrilled to announce that our CEO, Kurt Herpel, and CSO, Klaus Kratochwill, will ...
Read More
Get Involved
Learn how you can contribute to the exciting work happening at Delta4
Careers
Forging the innovative treatments of the future requires brilliant minds and we’re always on the lookout for talent.
Investors
Contact us to find out more about how you can invest with us and be a part of pioneering the next successful treatment.
Medical Community
Learn how you can partner with us and combine our technology with your knowledge to develop treatments faster.